GoldenGolden
Cluster: COVID-19

Cluster: COVID-19

A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.

All edits by  Mekala S 

Edits on 24 May, 2020
Mekala S
Mekala S edited on 24 May, 2020
Edits made to:
Article (+84/-5 characters)
Article

COVID-19 diagnostics and screening

Technology
Developer
Target(s)
Key components
Clinical use
Certificatiton or approval

OZO Diamond SARS-CoV-2 IgM/IgG Duo Rapid Test kit

OZO.Life

N Protein + S1 (RDB) Protein

One-step LFIA based IgM/IgG antibody rapid test kit. IgG Accuracy - 98.80%, IgM Accuracy - 99%

CECE-IVD Certified, EUAEU-Approved (CIBG, Ministry of Health, Welfare & Sport, Netherlands)

Mekala S
Mekala S edited on 24 May, 2020
Edits made to:
Article (+2 rows) (+10 cells) (+322/-20 characters)
Article

COVID-19 diagnostics and screening

Technology
Developer
Target(s)
Key components
Clinical use
Certificatiton or approval

OZO Gold SARS-CoV-2 IgM/IgG Duo Rapid Test kit

OZO.Life

N Protein

One-step LFIA based IgM/IgG Antibodyantibody Rapidrapid Testtest Kitkit. IgG accuracy = 98%, IgM accuracy = 94%

CE-IVD Certified, EU-Approved (CIBG, Ministry of Health, Welfare & Sport, Netherlands)

OZO RT-PCR Combo 1

OZO.Life

ORF 1ab and N gene

Detects the specfic nucleic acids from the SARS-CoV-2 Cirus. Sensitivity = 94.5% (CI:95%), Specificity = 98.96% (CI:95%)

CFDA, CE

OZO RT-PCR Combo 2

OZO.Life

ORF 1ab and N gene

Coronavirus RNA detection by one-step RT-PCR. Sensitivity = 100%, Specificity = 100%

CE

Mekala S
Mekala S edited on 24 May, 2020
Edits made to:
Article (+70/-3 characters)
Article

COVID-19 diagnostics and screening

Technology
Developer
Target(s)
Key components
Clinical use
Certificatiton or approval

OZO Diamond SARS-CoV-2 IgM/IgG Duo Rapid Test kit

OZO.Life

N Protein + S1 (RDB) Protein

One-step LFIA based IgM/IgG antibody rapid test kit. IgG Accuracy - 98.80%, IgM Accuracy - 99%

CE, EUA

OZO Gold SARS-CoV-2 IgM/IgG Duo Rapid Test Kitkit

OZO.Life

N Protein

One-step LFIA based IgM/IgG Antibody Rapid Test Kit. IgG accuracy = 98%, IgM accuracy = 94%

CE-IVD Certified, EU-Approved (CIBG, Ministry of Health, Welfare & Sport, Netherlands)

Mekala S
Mekala S edited on 24 May, 2020
Edits made to:
Article (+1 rows) (+5 cells) (+231 characters)
Article

COVID-19 diagnostics and screening

Technology
Developer
Target(s)
Key components
Clinical use
Certificatiton or approval

OZO Gold SARS-CoV-2 IgM/IgG Duo Rapid Test Kit

OZO.Life

N Protein

LFIA based IgM/IgG Antibody Rapid Test Kit. IgG accuracy = 98%, IgM accuracy = 94%

CE-IVD Certified, EU-Approved (CIBG, Ministry of Health, Welfare & Sport, Netherlands)

Mekala S
Mekala S edited on 24 May, 2020
Edits made to:
Article (+1/-53 rows) (+5/-244 cells) (+128/-244 characters)
Article

COVID-19 potential treatments and interventions

Treatment / intervention
Company/Team
Stage
Other uses
Mechanism of action

Actemra

Roche

Phase III

Anti-inflammatory

IL-6 inhibitor

AiRuiKa

Southeast Univ, China

Phase II

Treat pneumonia / sepsis

PD-1 inhibitor

Antibodies against SARS-CoV-2

preclinical

Antibody against CXCL10

Calm overactive immune response responsible for ARDS and ALI

Antibody against TLR4

Calm overactive immune response responsible for ARDS and ALI

APN01, recombinant ACE2

Clinical trials

Binds to virus preventing it from interacting with ACE2 receptor on lung cells

ASC09/ritonavir, lopinavir/ritonavir, with or without umifenovir

Clinical trials

HIV, influenza (umifenovir)

Aviptadil

NeuroRX

Phase II

Anti-inflammatory

IL-6 inhibitor

Bevacizumab (Avastin)

Clinical trial

Cancer

VEGF inhibitor, for lung complications

Brilacidin (treatment or vaccine)

Preclinical

Defensin memetic, immune system modulation

Approved in Japan for chronic pancreatitis, post operative reflux esophagitis

Inhibits protease TMPRSS2 which is needed for viral entry into cell

Clinical trials

Camrelizumab is used for hepatocellular carcinoma and Hodgkin lymphoma. Thymosin is used for the prevention of HCC in chronic hepatitis B and C and therapeutic treatment of HCC.

Humanized monoclonal antibody (mAb) targeting PD-1 (Camrelizumab)

CD24FC

OncoImmune

Phase III

Anti-inflammatory

IL-6 inhibitor

Colchicine

Montreal Health Institute

Phase III

Anti-inflammatory

Tubulin disruption

Convalescent plasma

Donald Arnold (McMaster University), Canadian Blood Services, Héma-Québec

Clinical trial upcoming

Plasma from recovered COVID-19 patients contains antibodies against SARS-CoV-2

Arturo Casadevall, Johns Hopkins University

FDA approval

Antibodies from serum of individual recovered from COVID-19 provide prevention or treatment

COVID-HIG, human immune globulin, antibody

Emergent BioSolutions, BARDA

Antibodies from recovered individuals

D-NAC, Dendrimer N-Acetyl Cysteine

Ashvattha Therapeutics, Johns Hopkins University

Clinical trials

Cytokine Storm Syndrome, Acute Respiratory Distress Syndrome

Convert reactive M1-like macrophages in cytokine storm syndrome into less reactive M2-like macrophages.

Clinical trials

Hepatitis C, HIV (ritonavir)

Hepatitis C protease inhibitor (Ganovo)

Clinical trial

HIV

Darunavir is an HIV-1 protease inhibitor, Cobicist is an inhibitor of cytochrome P450 (CYP)3A enzyme

Clinical trial

Influenza, Ebola

Viral RNA polymerase inhibitor, guanine analog

Page 1 of 3
...

COVID-19 diagnostics and screening

Technology
Developer
Target(s)
Key components
Clinical use
Certificatiton or approval

OZO Diamond

OZO.Life

N Protein + S1 (RDB) Protein

IgM/IgG antibody rapid test kit. IgG Accuracy - 98.80%, IgM Accuracy - 99%

CE, EUA

Page 1 of 2
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.